Thousands of Australians may receive life-changing medicine after the government agreed to fund a slew of new drugs used in the fight against type-2 diabetes.
The Pharmaceutical Benefits Scheme will extend funding Forxiga, Xigduo XR, Jardiance and Trajenta, which will be used in new triple-medicine therapies along with diabetes management drugs Qtern and Glyxambi.
Type-2 diabetes is a consequence of the obesity epidemic and represents about 85 per cent of all cases, Diabetes Australia says on its website.
The peak national body estimates two million Australians are at high risk of developing type-2 and may be showing early signs of the disease.
The drugs will be available from April 1.
